- Home
- PLRX vs MLYS Comparison
PLRX vs MLYS Comparison
Compare PLRX & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PLRX | MLYS |
|---|---|---|
| Founded | 2015 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 93.3M | 3.1B |
| IPO Year | 2020 | 2023 |
Fundamental Metrics
Financial Performance| Metric | PLRX | MLYS |
|---|---|---|
| Price | $1.35 | $35.11 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 7 |
| Target Price | $3.79 | ★ $47.33 |
| AVG Volume (30 Days) | 1.0M | ★ 1.5M |
| Earning Date | 11-06-2025 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.10 | $8.24 |
| 52 Week High | $13.68 | $47.65 |
Technical Indicators
Market Signals| Indicator | PLRX | MLYS |
|---|---|---|
| Relative Strength Index (RSI) | 53.12 | 36.49 |
| Support Level | $1.20 | $34.21 |
| Resistance Level | $1.27 | $36.61 |
| Average True Range (ATR) | 0.06 | 1.49 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 91.18 | 24.58 |
Price Performance
Historical ComparisonAbout PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.